Shareholders of PolyPeptide Group AG approved all proposals presented by the Board of Directors at the company's fifth annual General Meeting with substantial majority support. The meeting, chaired by Peter Wilden, had 26,780,855 shares with voting rights represented, accounting for 80.85% of the issued registered shares. All six members of the Board of Directors proposed for re-election were appointed for terms ending at the conclusion of the next annual General Meeting in 2027. Peter Wilden was re-elected as Chair of the Board of Directors, while Philippe Weber and Peter Wilden were each individually re-elected as members of the Remuneration and Nomination Committee for terms ending at the conclusion of the next annual General Meeting 2027.
The approval of these governance appointments matters because it provides continuity in leadership for a company operating in the specialized peptide-based active pharmaceutical ingredients market. PolyPeptide Group AG serves a rapidly growing market with significant exposure to metabolic diseases including GLP-1 therapies, making stable governance crucial for navigating this competitive and technically demanding sector. The company operates six GMP-certified facilities across Europe, the U.S. and India, and its shares trade on SIX Swiss Exchange under the symbol PPGN.
Additional proposals from the Board of Directors that received shareholder approval included the re-election of the Statutory Auditors and Independent Proxy, along with approval of the maximum aggregate compensation amounts for the Board of Directors and Executive Committee. Shareholders also granted discharge to all members of the Board of Directors and Executive Committee who served during the 2025 financial year for their activities in that period. This comprehensive approval demonstrates strong shareholder confidence in the company's current leadership and governance structures.
Financial matters received similar endorsement, with shareholders approving the Management Report, Statutory Financial Statements, Consolidated Financial Statements, and the report on non-financial matters for the 2025 financial year. The Remuneration Report 2025 was approved in a separate consultative vote. The minutes of the AGM 2026 will be available within 15 days on the company's website at https://polypeptide.com. The next annual General Meeting is scheduled for April 7, 2027. This broad shareholder support across all governance, financial, and operational matters indicates strong alignment between management and investors for a company positioned in the growing peptide therapeutics market.
